Operating Margin
-914%
Trailing 12 months · Through 30 Sep 2023
Comera Life Sciences Holdings, Inc. financial metrics
Period Q3 2023 · Filed 09 Nov 2023
Key metrics snapshot
Current Ratio
0.9x
Period-end balance · Through 30 Sep 2023
YoY relative change: -28%
Debt-to-equity
-0.73x
Period-end balance · Through 30 Sep 2023
Revenues YoY
-42%
Quarter · Through 30 Sep 2023
Profitability
| Metric | Latest value | YoY relative change |
|---|---|---|
| Operating Margin |
-914%
Trailing 12 months · 30 Sep 2023
|
Financial Health
| Metric | Latest value | YoY relative change |
|---|---|---|
| Current Ratio |
0.9x
Period-end balance · 30 Sep 2023
|
-28% |
| Debt-to-equity |
-0.73x
Period-end balance · 30 Sep 2023
|
Growth
| Metric | Latest value | YoY relative change |
|---|---|---|
| Revenues YoY |
-42%
Quarter · 30 Sep 2023
|
Share Metrics
| Metric | Latest value | YoY relative change |
|---|---|---|
| Entity Common Stock, Shares Outstanding |
30,737,796
Period-end balance · 08 Nov 2023
|
+55% |
| Common Stock, Shares, Outstanding |
30,737,796
Period-end balance · 30 Sep 2023
|
+85% |
| Common Stock, Value, Issued |
$2,759
Period-end balance · 30 Sep 2023
|
+66% |
| Weighted Average Number of Shares Outstanding, Basic |
23,113,051
Reported period · 30 Sep 2023
|
+44% |
| Weighted Average Number of Shares Outstanding, Diluted |
23,113,051
Reported period · 30 Sep 2023
|
+44% |
Supporting Metrics
These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.
| Metric | Latest value | YoY relative change |
|---|---|---|
| Accounts Payable, Current |
$1,144,822
Period-end balance · 30 Sep 2023
|
-20% |
| Assets |
$3,071,949
Period-end balance · 30 Sep 2023
|
-38% |
| Assets, Current |
$2,630,496
Period-end balance · 30 Sep 2023
|
-39% |
| Cash and Cash Equivalents, at Carrying Value |
$1,767,870
Period-end balance · 30 Sep 2023
|
-34% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
$1,817,870
Period-end balance · 30 Sep 2023
|
-33% |
| Common Stock, Par or Stated Value Per Share |
0
Period-end balance · 30 Sep 2023
|
0% |
| Common Stock, Shares Authorized |
150,000,000
Period-end balance · 30 Sep 2023
|
0% |
| Common Stock, Shares, Issued |
30,737,796
Period-end balance · 30 Sep 2023
|
+85% |
| Cost of Revenue |
$264,880
Trailing 12 months · 30 Sep 2023
|
-31% |
| Depreciation |
$99,433
Trailing 12 months · 30 Sep 2023
|
-4.2% |
| Earnings Per Share, Basic |
3
Trailing 12 months · 30 Sep 2023
|
+50% |
| Earnings Per Share, Diluted |
3
Trailing 12 months · 30 Sep 2023
|
+50% |
| General and Administrative Expense |
$8,447,683
Trailing 12 months · 30 Sep 2023
|
-19% |
| Income Tax Expense (Benefit) |
$0
Trailing 12 months · 30 Sep 2023
|
|
| Interest Expense |
$5,965
Reported period · 30 Sep 2023
|
-53% |
| Lessee, Operating Lease, Liability, to be Paid |
$177,463
Period-end balance · 30 Sep 2023
|
-55% |
| Lessee, Operating Lease, Liability, to be Paid, Year One |
$123,077
Period-end balance · 30 Sep 2023
|
-43% |
| Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
$5,867
Period-end balance · 30 Sep 2023
|
-79% |
| Liabilities |
$2,969,685
Period-end balance · 30 Sep 2023
|
-24% |
| Liabilities and Equity |
$3,071,949
Period-end balance · 30 Sep 2023
|
-38% |
| Liabilities, Current |
$2,932,419
Period-end balance · 30 Sep 2023
|
-15% |
| Nonoperating Income (Expense) |
$137,605
Trailing 12 months · 30 Sep 2023
|
|
| Operating Income (Loss) |
-$9,146,842
Trailing 12 months · 30 Sep 2023
|
+15% |
| Operating Lease, Liability |
$171,596
Period-end balance · 30 Sep 2023
|
-53% |
| Operating Lease, Liability, Current |
$171,596
Period-end balance · 30 Sep 2023
|
-12% |
| Operating Lease, Right-of-Use Asset |
$161,515
Period-end balance · 30 Sep 2023
|
-55% |
| Operating Lease, Weighted Average Discount Rate, Percent |
0.08
Period-end balance · 30 Sep 2023
|
0% |
| Property, Plant and Equipment, Gross |
$759,397
Period-end balance · 30 Sep 2023
|
+14% |
| Property, Plant and Equipment, Net |
$186,738
Period-end balance · 30 Sep 2023
|
-3% |
| Research and Development Expense |
$1,434,679
Trailing 12 months · 30 Sep 2023
|
-7.3% |
| Retained Earnings (Accumulated Deficit) |
-$40,950,566
Period-end balance · 30 Sep 2023
|
-28% |
| Revenue from Contract with Customer, Excluding Assessed Tax |
$1,000,400
Trailing 12 months · 30 Sep 2023
|
-42% |
| Share-based Payment Arrangement, Expense |
$996,099
Trailing 12 months · 30 Sep 2023
|
+110% |
| Stockholders' Equity Attributable to Parent |
-$4,220,602
Period-end balance · 30 Sep 2023
|
-23% |
Comparisons, sources and research notes
Sources and sharing
Comera Life Sciences Holdings, Inc. Financial Facts
- Context
- Latest metrics period: Q3 2023
- Latest reported value
- Operating Margin -914%
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Tracking and update notes
Why revisit this company facts page
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
- Latest source-backed update
- Latest metrics period Q3 2023
- Why come back
- Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
- Current latest metrics period: Q3 2023.
- Most recent SEC facts end date on this page: 08 Nov 2023.
- Save this filer to return when the next filing-backed metric period changes the picture.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest update for Comera Life Sciences Holdings, Inc.
Latest financial period: Q3 2023. Reopen this facts page to verify the newest reported period against the prior baseline.
Update date
09 Nov 2023
Page type
Company facts
Latest period
Q3 2023
SEC-backed company facts were refreshed from filings filed on 09 Nov 2023.
Benchmark Context
How Operating Margin compares
Operating Margin does not yet have enough prior-period data for a historical comparison on this page.
Compared with
Compared with Comera Life Sciences Holdings, Inc.'s recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.
Why this is notable
Operating Margin already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.
- Latest comparable period on this page: Q3 2023.
- Peer context will appear when enough companies report a comparable value for this metric.
- Open the metric history first if you want to verify the exact period-to-period change.
Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.
How to read key metrics on this page
These short guides explain what the headline metrics mean, what to compare next, and where to open the live SEC-backed example for this company.
Plain-English Guide
How to read Revenue on this page
Revenue is the sales a company reports from customers before most expenses are subtracted.
Why people care
People start here to understand business scale and whether demand is growing before they ask about margins or cash flow.
How to read it
Check the latest reported period first, then compare the same quarter or year against prior periods so seasonality does not distort the story.
Compare next
Compare revenue with gross profit, operating income, and operating cash flow to see whether sales are turning into healthy economics.
Revenue can jump because of acquisitions, pricing changes, or revenue-recognition rules, and reporting periods may differ across companies.
Open a live SEC-backed example
Filing notes and source
Key facts
- Comera Life Sciences Holdings, Inc. financial facts use SEC filings; any third-party reference is labeled separately.
- Latest metrics period on this page: Q3 2023.
- Headline metric: Operating Margin -914%.
Change
- Comparable YoY change is unavailable for this metric.
- Most recent SEC facts end date: 08 Nov 2023.
Research use
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Metric cards link to SEC history; a third-party reference may use a different or unverified reporting period.
Evidence
Based on latest 10-Q/10-K
View source filing
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Latest financial snapshot (2023-11-08) highlights Operating Margin -914.3%, Current Ratio 0.9x, and Debt-to-equity -0.73x.
Valuation Snapshot
SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.
No market comparison
No market comparison
Low confidence
USD inputs only. Cash and complete debt must share the latest balance date. Missing balances are unknown, never zero; equity value and market EV remain unavailable until both are verified.
Fair value per share
n/a
Market price
n/a
PEG ratio
n/a
Enterprise value
-$98.38M
Equity value
n/a
DCF fair value scenarios
Bear
n/a
- Growth
- 1%
- Discount
- 11%
- Terminal
- 2%
Base
n/a
- Growth
- 4%
- Discount
- 10%
- Terminal
- 2.5%
Bull
n/a
- Growth
- 7%
- Discount
- 9%
- Terminal
- 3%
Base growth: DCF Growth Assumption.
Key valuation metrics
EV/Revenue
n/a
Market price market EV / SEC revenue
Market enterprise value is unavailable
EV/EBITDA
n/a
Market price market EV / SEC EBITDA
Market enterprise value is unavailable
P/E
n/a
Market price market price / SEC EPS
Market cap is unavailable
P/S
n/a
Market price market cap / SEC revenue
Market cap is unavailable
P/B
n/a
Market price market cap / SEC equity
Market cap is unavailable
PEG
n/a
P/E / DCF Growth Assumption
P/e or positive growth is unavailable
Core assumptions
- Projection
- 5 years
- FCF growth
- 4%
- Discount rate
- 10%
- Terminal growth
- 2.5%
SEC fact inputs
- DCF base FCF
- -$6.76M
- Trailing SEC FCF
- Reported FCF
- -$6.76M
- Net income
- -$9.01M
- EBITDA
- -$9.05M
- Cash
- $1.77M
- Debt
- n/a
- Equity
- -$4.22M
- Shares
- 23,113,051
Input periods, units and SEC sources
Equity value = DCF enterprise value + cash − debt. Cash flow uses matching annual or trailing-12-month periods.
- Operating cash flow: -6,661,065.0 USD · through 2023-09-30 · prior annual + current YTD − prior YTD SEC source SEC source SEC source
- Capital expenditures: 94,009.0 USD · through 2023-09-30 · prior annual + current YTD − prior YTD SEC source SEC source SEC source
- Cash and equivalents: 1,767,870.0 USD · through 2023-09-30 SEC source
- Debt: unavailable on a verified comparable basis
Data confidence notes
- Debt unavailable: no complete usd debt balance at the latest balance date
- Dcf base free cash flow: dcf base starts from trailing sec free cash flow
- Dcf base free cash flow: trailing free cash flow is not positive
- Dcf confidence is low for this sec-only free cash flow estimate
- Ticker missing for issuer
- Debt missing: equity value and market ev unavailable
- Base free cash flow is negative; dcf output is mechanically computed but high risk
- Peg unavailable: market price is missing
Compare This Company Through SEC-backed Metrics
Use these links to compare Comera Life Sciences Holdings, Inc. against other SEC filers on the same metric, then verify the company history from the paired facts page.
Revenues YoY
Latest value: -42%
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
29.1/100
Weak Confidence low
Financial Health
- Current Ratio
- 0.9x
- Debt to Equity
- -0.73x
Strengths
Current Ratio
Watchpoints
Operating Margin, Debt-to-equity, and Revenues YoY
Calculation methodology and other links
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- Operating Income / Revenues using matching TTM or quarter periods; basis shown per metric
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- Revenues YoY using available TTM or quarter comparison; basis shown per metric
- Net Income YoY using available TTM or quarter comparison; basis shown per metric
CIK / security context first